Clinical Trial Update: S0217, Adjuvant Cisplatin and Docetaxel After Complete Resection Stage III or IV Head and Neck Cancer [Phase 2]

View source ↗

Summary

The SWOG Phase 2 trial S0217 evaluating adjuvant cisplatin and docetaxel after complete resection in Stage III/IV head and neck cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer

Drugs mentioned

• Cisplatin (Platinol) (cisplatin)
• Docetaxel (Taxotere) (docetaxel)

Snippet

Sponsor: SWOG Cancer Research Network | Conditions: Head and Neck Cancer | Phase 2 | Status: WITHDRAWN